SeriesAntiphospholipid antibodies and thrombosis
Section snippets
Antiphospholipid syndrome
Autoantibodies with apparent specificity for negatively charged phospholipids have long been recognised in systemic lupus erythematosus and are associated with thrombotic complications and miscarriage.1, 2 The terms lupus anticoagulant and anticardiolipin are used to describe these antibodies.
The antiphospholipid syndrome may be defined as the occurrence of thrombosis, recurrent miscarriage, or both in association with laboratory evidence of persistent antiphospholipid antibody, 3 either lupus
Antiphospholipid antibodies
Lupus anticoagulant is an immunoglobulin that acts as a coagulation inhibitor, but does not recognise a specific coagulation factor. Lupus anticoagulant slows the rate of thrombin generation, and therefore clot formation in vitro, through interference in the interactions that require phospholipid. It is therefore detected in coagulation assays. The criteria for lupus anticoagulant positivity are an increased clotting time in a phospholipid dependent coagulation test, with evidence of an
Thrombosis in antiphospholipid syndrome
The paradoxical association between a prothrombotic state and the presence of autoantibodies with in-vitro anticoagulant effects is not fully understood. In antiphospholipid syndrome, vascular occlusion is due to thromboembolism, rather than vasculitis. Some arterial events may also be caused by embolisation from sterile vegetations on cardiac valves. Patients with antiphospholipid syndrome have evidence of persistent coagulation activation; there is an increased plasma concentration of markers
Difficulties with diagnosis
Antiphospholipid syndrome is clearly a heterogeneous disorder, both in terms of its clinical manifestations and range of autoantibodies. Because of the perceived high risk of recurrent thrombosis in antiphospholipid syndrome and the efficacy of oral anticoagulant therapy, accurate diagnosis is a clinical imperative.
Diagnosis is dependent on the maintenance of a high index of suspicion and confirmation through laboratory investigation. When arterial or venous thrombosis occur in patients who do
Management of thrombosis and miscarriage
The diagnostic difficulties and range of clinical manifestations in antiphospholipid syndrome make the need for liaison between clinical and laboratory specialists essential in the formulation of strategies for clinical management. There are only limited data from prospective clinical trials on which to base treatment decisions. Therapeutic regimens should be guided by the results of observational studies that support an association between antiphospholipid antibodies and thrombosis,
Future aims
Our understanding of the pathogenesis and clinical features of autoimmune thrombotic disease is increasing rapidly. Antiphospholipid syndrome is a multifaceted and complex condition that is clinically demanding with regard to diagnosis and management. There is a clear need for further studies of the mechanisms involved, for the development of more specific laboratory techniques to identify those patients at increased risk of thrombosis and miscarriage, and for the enrolment of patients in
References (65)
- et al.
Antiphospholipid antibodies and venous thromboembolism
Blood
(1995) - et al.
Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor
Lancet
(1990) - et al.
Measurement of antiphospholipid antibodies by ELISA using beta2-glycoprotein I as an antigen
J Immunol Methods
(1991) - et al.
Differential effects of anti-beta 2 glycoprotein I antibodies on the anticoagulant activity of activated protein C
Blood
(1998) - et al.
Antiphosphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenetic mechanism?
Blood
(1993) - et al.
Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes
Blood
(1994) - et al.
Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis
Am J Obst Gynaecol
(1993) - et al.
Action of anticardiolipin and antibodies to beta2-glycoprotein -I on trophoblast proliferation as a mechanism for fetal death
Lancet
(1998) - et al.
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four year prospective study from the Italian Registry
Am J Med
(1996) - et al.
Anticardiolpin antibodies: clinical consequences of “low titers”
Obst Gynecol
(1996)
Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans and thrombosis
J Paediatrics
HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA)
J Autoimmunity
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaboration study (1SCOAT)
Lancet
Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk
Am J Cardiol
Thrombosis and systemic lupus erythematosus despite circulating anticoagulants
J Lab Clin Med
Acquired inhibitors of blood coagulation
Prog Haemostasis Thrombosis
Guidelines on testing for the lupus anticoagulant
J Clin Pathol
Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta2-glycoprotein I (apolipoprotein H)
Proc Nat Acad Sci USA
“Anticardiolipin” autoantibodies recognise beta2-glycoprotein I in the absence of phospholipid: importance of antigen density and bivalent binding
J Immunol
Beta2-glycoprotein I (beta2-GPI) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies
Br J Immunol
Some `antiphospholipid antibodies' bind to beta 2-glycoprotein I in the absence of phospholipid
Br J Haematol
Anti-beta 2-glycoprotein I (beta 2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta 2GPI binding to phospholipids
Clin Invest
Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
Thromb Haemost
Anti beta2 glycoprotein I antibodies: detection and association with thrombosis
Br J Haematol
Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor
J Immunol
Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies
Br J Haematol
Resistance to activated protein C
N Engl J Med
Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody
Am J Haematol
Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome
Br J Haematol
Characterisation and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in the primary antiphospholipid syndrome (APS)
Clin Exp Immunol
Anti-endothelial cell antibodies to the endothelial hybridoma cell line (Eahy926) in systemic lupus erythematosus patients with antiphospholipid antibodies
Br J Haematol
Beta2-glycoprotein I deficiency and the risk of thrombosis
Thromb Haemost
Cited by (288)
The spectrum of COVID-19-associated chorioretinal vasculopathy
2023, American Journal of Ophthalmology Case ReportsBilateral Choroidal Occlusion in Antiphospholipid Syndrome Associated with Systemic Lupus Erythematosus
2017, Chinese Medical Sciences JournalFetal Loss
2013, Emery and Rimoin's Principles and Practice of Medical GeneticsNatural anticoagulants and thrombophilia
2011, Blood and Bone Marrow Pathology